X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Through the acquisition, Sentynl will commercialize the Zokinvy (lonafarnib) globally. It is the first and only treatment approved by the U.S. FDA to target the cause and symptoms of progeria, also known as Hutchinson-Gilford progeria syndrome.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sentynl Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 03, 2024
Details:
Zokinvy (lonafarnib) is a first-in-class farnesyltransferase inhibitor. It is approved for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AnGes
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Lonafarnib is a first-in-class, oral prenylation inhibitor which inhibits a host enzyme, blocking a critical step in HDV viral assembly. Lonafarnib has been dosed in over 450 chronically infected HDV patients across global clinical sites, including the Phase 3 D-LIVR study.
Lead Product(s): Lonafarnib
Therapeutic Area: Infections and Infectious Diseases Product Name: Zokinvy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Zokinvy® (lonafarnib), is a first-in-class disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Progeria Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
Sarasar (lonafarnib) is a well-characterized, first-in-class, inhibitor of farnesyl-transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle.
Lead Product(s): Lonafarnib,Peginterferon Lambda,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarasar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Zokinvy (lonafarnib), is a well-characterized, first-in-class, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation.
Lead Product(s): Lonafarnib,Peginterferon Lambda,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Zokinvy
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Zokinvy (lonafarnib) is a first-in-class disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with HGPS.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy (lonafarnib) in Japan and will be the exclusive partner for distribution and commercialization.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AnGes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
Details:
Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
Details:
Zokinvy is the first and only FDA approved therapy to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
The PRV was granted in conjunction with the recent approval by the U.S. Food and Drug Administration of ZokinvyTM (lonafarnib) for treatment of Progeria and processing-deficient Progeroid Laminopathies.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Progeria Research Foundation
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Divestment November 23, 2020
Details:
Zokinvy is a disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Progeria. In patients with Progeria, Zokinvy reduced the incidence of mortality by 60% and increased average survival time by 2.5 years.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
LIFT is a Phase 2, open-label study of 26 adult patients with chronic HDV treated with Lambda 180 mcg once weekly in combination with Lonafarnib 50 mg boosted with ritonavir 100 mg twice daily for 24 weeks followed by 24 weeks of post-treatment follow-up.
Lead Product(s): Peginterferon Lambda,Lonafarnib,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Lambda
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
Lambda is a well-characterized, first in class, type III interferon (IFN) that stimulates immune responses that are critical for the development of host protection during viral infections. Lambda is Phase 3 ready in development as a treatment for HDV.
Lead Product(s): Peginterferon Lambda,Lonafarnib,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Pegasys
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
LIFT is a Phase 2a open-label study of 26 adult patients with chronic HDV treated with Lambda 180 mcg once weekly in combination with Lonafarnib 50 mg boosted with ritonavir 100 mg twice daily for 24 weeks.
Lead Product(s): Peginterferon Alfa 2A,Lonafarnib,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Pegasys
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
The Zokinvy NDA is backed by the data from a study published in Journal of the American Medical Association (JAMA) which demonstrated a survival benefit with an 88% reduction in the risk of mortality in patients with Progeria treated with lonafarnib monotherapy.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
European Medicines Agency has completed its validation of the Marketing Authorization Application for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
HDV Phase 3 D-LIVR Study is in Progress. Eiger is supplying Peginterferon Lambda and is assisting in the protocol design to initiate study.
Lead Product(s): Lonafarnib,Ritonavir,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
Lonafarnib is a first-in-class, oral farnesyltransferase inhibitor which has demonstrated extended survival in children and young adults with Progeria.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
